First, glioblastoma cells were exposed to different doses of multi-kinase inhibitor dactolisib (PI3K, mTOR), pan-AKT inhibitors ipatasertib and MK-2206, multi-kinase inhibitor regorafenib (e.g., various receptor tyrosine kinases, B-RAF), or MEK inhibitor trametinib, respectively. Here, MAP2K7 is linked to glioblastoma.